MedPath

MEDIVATION, INC.

🇺🇸United States
Ownership
Private
Established
1997-01-01
Employees
-
Market Cap
-
Website

Clinical Trials

100

Active:80
Completed:13

Trial Phases

3 Phases

Phase 1:46
Phase 2:6
Phase 3:11

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (63 trials with phase data)• Click on a phase to view related trials

Phase 1
46 (73.0%)
Phase 3
11 (17.5%)
Phase 2
6 (9.5%)

Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2
Withdrawn
Conditions
Lymphoma, Large B-Cell, Diffuse
Primary Mediastinal Large B-cell Lymphoma
Transformed Indolent Lymphoma
First Posted Date
2016-01-13
Last Posted Date
2016-11-25
Lead Sponsor
Medivation, Inc.
Registration Number
NCT02653989

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Phase 2
Completed
Conditions
Malignant Melanoma
Melanoma
Interventions
First Posted Date
2011-09-16
Last Posted Date
2016-01-21
Lead Sponsor
Medivation, Inc.
Target Recruit Count
103
Registration Number
NCT01435369
Locations
🇺🇸

Yale University School of Medicine, Section of Med Onc., New Haven, Connecticut, United States

🇺🇸

Moffitt Cancer Center Cutaneous Oncology Department, Tampa, Florida, United States

🇺🇸

Northwestern Memorial Hospital, Chicago, Illinois, United States

and more 15 locations

An Extension of the CONCERT Protocol (DIM18)

Phase 3
Terminated
Conditions
Alzheimer's Disease
Interventions
First Posted Date
2010-06-29
Last Posted Date
2016-09-27
Lead Sponsor
Medivation, Inc.
Target Recruit Count
672
Registration Number
NCT01152216

An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease

Phase 3
Terminated
Conditions
Huntington Disease
Interventions
First Posted Date
2010-03-11
Last Posted Date
2016-10-12
Lead Sponsor
Medivation, Inc.
Target Recruit Count
362
Registration Number
NCT01085266

A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease

Phase 3
Terminated
Conditions
Moderate to Severe Alzheimer
Interventions
Drug: Placebo
First Posted Date
2009-08-07
Last Posted Date
2016-09-27
Lead Sponsor
Medivation, Inc.
Target Recruit Count
89
Registration Number
NCT00954590
  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy